AtriCure (NASDAQ:ATRC) Hits New 52-Week High – Time to Buy?

AtriCure, Inc. (NASDAQ:ATRC)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $44.80 and last traded at $44.6980, with a volume of 51505 shares trading hands. The stock had previously closed at $44.30.

Wall Street Analysts Forecast Growth

ATRC has been the topic of several recent research reports. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Stock Performance

The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $33.91 and a 200-day moving average price of $31.47. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 215.67 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the sale, the director owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 47,246 shares of company stock valued at $1,777,845. 4.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATRC. AQR Capital Management LLC raised its holdings in AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after purchasing an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after purchasing an additional 1,230 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after buying an additional 8,956 shares in the last quarter. Jane Street Group LLC raised its stake in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after buying an additional 87,553 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of AtriCure in the 1st quarter worth $158,000. 99.11% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.